Posted on 26/11/2009 in Pharmaceutical Company Product News Cephalon and Ception have announced that a study into the drug CINQUIL (reslizumab), upon which the firms have been collaborating, has yielded a positive outcome.
The drug is being investigated as a treatment option for those with paediatric eosinophilic esophagitis.
Patients treated with CINQUIL demonstrated a significant reduction in esophageal eosinophil levels when compared to a placebo treatment, the study showed.
However, the study did not reach its primary endpoint, but demonstrated that that the treatment was well-tolerated.
Steve Tullman, chief executive officer at Ception, stated: "We will continue to review the data from this study and from our ongoing open-label study to find the best path forward for CINQUIL for the treatment of eosinophilic esophagitis."
Earlier this month, Cephalon revealed that its drug Treanda (bendamustine HCI) provoked a durable response in patients suffering from relapsed indolent non-Hodgkin's Lymphoma during trial phase.
Other news stories from 26/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
